Trending stocks today
Medpace Holdings (MEDP-Q)
NASDAQ:MEDP
376.04
4.04
(1.09%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 1 opinions in the last 12 months.
Experts generally agree that Medpace Holdings (MEDP-Q) is a solid clinical research company that focuses on helping smaller biotechs navigate the path to commercialization. They have strong fundamentals and are expected to see solid top-line growth over the next two years. While some express concern about valuation at 30X forward earnings, the overall outlook is positive based on earnings and interest rates.
N/A
Unknown
- «
- ‹
- 1
- ›
- »
Medpace Holdings(MEDP-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Medpace Holdings(MEDP-Q) Frequently Asked Questions
What is Medpace Holdings stock symbol?
Medpace Holdings is a American stock, trading under the symbol MEDP-Q on the NASDAQ (MEDP). It is usually referred to as NASDAQ:MEDP or MEDP-Q
Is Medpace Holdings a buy or a sell?
In the last year, 1 stock analyst published opinions about MEDP-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Medpace Holdings.
Is Medpace Holdings a good investment or a top pick?
Medpace Holdings was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Medpace Holdings.
Why is Medpace Holdings stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Medpace Holdings worth watching?
In the last year, there was no coverage of Medpace Holdings published on Stockchase.
What is Medpace Holdings stock price?
On 2024-04-22, Medpace Holdings (MEDP-Q) stock closed at a price of $376.04.
MEDP is a clinical research company that helps smaller biotechs perform research and navigate/move along the pathway to commercialization. They tend to focus on smaller companies, so they tend to feel the booms and busts a bit more than peers but we view it as a solid company that has navigated the last few years well. Fundamentals are quite strong as well and the growth on the top-line is solid in the 15% range over the next two years expected. We think the big question comes down to valuation at 30X forward earnings. We would be comfortable buying it based on the outlook for its earnings and interest rates.
Unlock Premium - Try 5i Free